-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $53

Benzinga·02/25/2026 13:23:35
Listen to the news
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $50 to $53.